Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects. (ClinicalTrials.gov number, NCT00073307 ClinicalTrials.gov.).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Escudier et al. (Wed,) studied this question.

synapsesocial.com/papers/69d9631a8988aeabbe68518d https://doi.org/https://doi.org/10.1056/nejmoa060655

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1End Points and United States Food and Drug Administration Approval of Oncology Drugs2003 · 480 citations
2Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006)2006 · 27 citations
3Prognostic factors in metastatic renal cell carcinoma after failure of immunotherapy: Lessons from a large phase III trial2004 · 9 citations
4Prognostic factors in metastatic renal cell carcinoma after failure of immunotherapy: Lessons from a large phase III trial2004 · 4 citations
5Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.1999 · 515 citations

Bookmark

View Full Paper